Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Psychotic Disorders

• ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
• Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
• ACP-204 in Adults With Alzheimer's Disease Psychosis
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
• Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
• Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
• Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease
• Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
• Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
• Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
• Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
• Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
• Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
• A Randomized Controlled Trial With Rituximab - for Schizophrenia Spectrum Disorder in Adults
• Comparing Antipsychotic Medications in LBD Over Time
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease Dementia
• A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
• Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
• Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers
• Effects Zulresso on Postpartum Psychosis
• Examining the Effects of Estradiol on Neural and Molecular Response to Reward
• Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
• M1 Schizophrenia PET Study
• Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
• D-serine AudRem: R33 Phase
• Mind to Quit Multisite Trial
• Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
• Sodium Nitroprusside in Early Course Schizophrenia
• Relative Bioavailability of LY03010 Compared to Listed Drug
• Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia
• Acetazolamide for Treatment Resistant Schizophrenia
• Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
• Add-on MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis
• Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
• Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
• Antipsychotic Response to Clozapine in B-SNIP Biotype-1 (Clozapine)
• A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder
• Pharmacological Modulation of Hippocampal Activity in Psychosis 2
• Psychotherapy for Psychosis, Adverse Events, and Substance Misuse
• Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
• Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
• Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis
• Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)
• Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement
• R33: Levetiracetam in Early Psychosis
• Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
• Pharmacologic Modulation of Hippocampal Activity in Psychosis
• Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
• Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders
• Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
• Bazedoxifene -Treatment for Women With Schizophrenia
• Cannabidiol for Treatment of Recent-onset Psychosis With Comorbid Cannabis Use
• Estradiol as add-on to Antipsychotics
• L-arginine Study for Persistent Symptoms of Schizophrenia
• The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
• Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness
• Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
• A Rater-blinded RCT to Compare Effectiveness of EMDR vs TAU in Patients With First Episode Psychosis and History of Psychological Trauma
• Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
• Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
• Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders
• Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
• Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
• Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up
• Persistence Targeted Smoking Cessation in Schizophrenia
• Telmisartan Pilot Study on Treatment Resistant Schizophrenia
• Effects of Acute Prucalopride Administration in Healthy Volunteers
• Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
• Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
• Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
• Comparison of Drugs on Headache Treatment After ECT Treatment
• Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
• Treating Smokers With Mental Illness
• Cromoglycate Adjunctive Therapy for Outpatients With Schizophrenia
• A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
• D-serine Augmentation of Neuroplasticity
• Exogenous Melatonin in Intensive Care Unit Chronodisruption
• BXCL501 for Agitation in Schizophrenia
• Cognitive Effects of Nimodipine in Patients With Schizophrenia
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
• SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
• Acceptable Hemodynamic Changes in Dexmedetomidine for Single Intravenous Bolus Injection
• Prebiotic Treatment in People With Schizophrenia
• Effects of Seven Day Prucalopride Administration in Healthy Volunteers
• A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
• Research Into Antipsychotic Discontinuation and Reduction Trial
• Brexpiprazole Study
• Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
• Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
• Substance Misuse To Psychosis for Stimulants
• A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia
• A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
• Mindfulness-based Social Cognition Training for Psychosis (SocialMind): A Feasibility Study
• The Norwegian Prednisolone in Early Psychosis Study
• Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
• Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
• Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)
• This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
• A Clinical Trial of Intravenous Ganaxolone in Women With Postpartum Depression
• Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831
• IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
• "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"
• Levetiracetam in Early Psychosis
• Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up
• Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia
• A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
• Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
• Berberine as Adjuvant Treatment for Schizophrenia Patients
• Clinical Trial of AVL-3288 in Schizophrenia Patients
• A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
• Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
• Prednisolone Addition for Patients With Recent-onset Psychotic Disorder
• Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
• Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
• The Role of Nitric Oxide in Cognition in Schizophrenia
• Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
• Tocilizumab in Schizophrenia
• Striatal Connectivity and Clinical Outcome in Psychosis
• Sulforaphane to Reduce Symptoms of Schizophrenia
• Topiramate and Schizophrenia: Effects on Weight and Psychopathology
• Siltuximab in Schizophrenia
• MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
• Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia
• Expanded Access of Pimavanserin for Patients With PD Psychosis
• The Staged Treatment in Early Psychosis Study
• The Sustained Effects of Ketamine
• Aspirin in Young Psychotic Patients
• Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia
• Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
• Cbt for Psychosis and Affect on Psychosis Symptoms
• Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
• Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
• A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
• Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
• Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana
• Antipsychotics and Risk of Hyperglycemic Emergencies
• Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
• Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581
• Adult Study Oxytocin - Behavioral
• Gabapentin in Patients at Clinical Risk for Psychosis
• Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
• Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
• Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
• Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
• Role Functioning Changes NOS
• Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
• Cannabidiol Treatment in Patients With Early Psychosis
• Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study
• Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
• A Pharmacokinetic Study of Paliperidone ER
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
• Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
• Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
• Cannabinoids, Learning, and Memory
• Fluoxetine vs Aripiprazole Comparative Trial (FACT)
• Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients
• Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
• Study of the Effect of Dosing on Clozapine Levels
• Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia
• Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
• Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
• Novel Smoking Cessation Drug for Schizophrenia
• Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective
• Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
• Lurasidone Effects on Tissue Glutamate in Schizophrenia
• Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
• Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
• Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients
• An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
• Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
• Effects of Metformin and Fish Oil on Treatment With Clozapine
• Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia
• Antipsychotic to Treat Psychosis Syndrome
• Treatment of Psychosis and Agitation in Alzheimer's Disease
• Minocycline Augmentation to Clozapine
• Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
• Probing the Cannabinoid System in Individuals With a Family History of Psychosis
• Association of Amisulpride Response in Schizophrenia With Brain Image
• Bioavailability of LY03004 and Risperdal® Consta®
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
• Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
• RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
• Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
• Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
• Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
• Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
• Glutamate, Brain Connectivity and Duration of Untreated Psychosis
• Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.
• Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
• A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
• Simvastatin Addition for Patients With Recent-onset Schizophrenia
• Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder
• D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
• Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?
• A Study of Combination Therapy in Children With ADHD
• Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis
• Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia
• Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
• Antipsychotic Effects on Brain Function in Schizophrenia
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia
• Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
• Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
• Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
• Naltrexone for Antipsychotic-Induced Weight Gain
• A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
• An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
• Cannabinoids and Cerebellar-Motor Functioning
• A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis
• Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)
• Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
• Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia
• Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
• Omega-3 Dietary Supplements in Schizophrenia
• Helping Those With Mental Illness Quit Smoking
• Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis
• Oxytocin and CBSST for People With Schizophrenia
• Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI
• Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
• A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
• The Role of Antidepressants or Antipsychotics in Preventing Psychosis
• Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders
• Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis
• Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia
• Kuvan in People With Schizophrenia and Schizoaffective Disorder
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
• Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
• Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy
• Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo
• Randomized Double Blind Placebo Control Study in Patients With Schizophrenia
• Salsalate as an Adjunctive Treatment for Patients With Schizophrenia
• First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia
• Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
• Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen
• Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)
• Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
• Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania
• RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
• Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
• N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia
• POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
• Bergen Psychosis Project 2 - The Best Intro Study
• Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
• NAPLS Omega-3 Fatty Acid Versus Placebo Study
• Sustaining Remission of Psychotic Depression
• Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
• Nicotinic Receptors and Schizophrenia
• F-18 Altanserin PET Study of Patients Receiving Clozapine
• Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
• NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
• A Follow up Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
• A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers
• Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)
• Special Drug Use Investigation for PAXIL Tablet (Long-term)
• Drug Use Investigation for PAXIL Tablet
• To Rescue Cognition With Valaciclovir
• Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
• Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
• Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)
• N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
• The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
• Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
• Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
• Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
• Optimization of Treatment and Management of Schizophrenia in Europe
• Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract(YY-162)in Children With ADHD
• Effectiveness of Ziprasidone for Patients With Schizophrenia
• A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
• Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone
• Efficacy and Safety of Paliperidone ER in First Episode Psychosis
• Efficacy and Safety With Ziprasidone in First-episode Psychosis
• A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
• A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
• A Comparison of Long-acting Injectable Medications for Schizophrenia
• Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
• Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
• Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia
• Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone
• Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis
• A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
• A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
• Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia
• Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
• Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
• DECIFER: Depression and Citalopram In First Episode Recovery
• Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
• Oxytocin Treatment of Schizophrenia
• Efficacy and Safety of Aripiprazole in First Episode Psychosis
• Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
• Treatment of Alcohol Dependence and Comorbid Bipolar Disorder
• Vitamin D Supplementation in Psychiatric Illnesses
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
• A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders
• Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
• Effects of Delta-9-THC and Iomazenil in Healthy Humans
• Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
• Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation
• D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
• Seroquel Alone Versus Seroquel With an SSRI for Depression With Psychotic Symptoms
• To Demonstrate the Relative Bioequivalency of Generic Haloperidol Tablets Versus Haldol in Normal Volunteers
• Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
• Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder
• Use, Effects and Side-effects of Second-generation Antipsychotics in a Naturalistic Setting
• Role of Anti-Inflammatory Agents in Patients With Schizophrenia
• Polypharmacy in Clozapine-resistant Schizophrenia
• Role of Minocycline in First Episode Psychosis
• Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
• An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED)
• Treatment of Psychotic Major Depression With Mifepristone
• Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
• Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
• Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
• Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
• Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
• Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
• Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
• Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia
• 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study
• Biomarkers in Schizophrenia
• Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics
• A Study to Assess the Effect of Single and Multiple Doses Org 50081 and a Single Dose of Zopiclone on Next-day Driving Ability and Psychomotor Performance in Healthy Volunteers. (P05794) (COMPLETED)
• Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
• A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation
• Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
• A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone
• Ziprasidone vs Standard Therapy for Agitated Patients in the ED
• A Follow up Safety Study of Patients Who Participated in Previous Studies of the Drug Org 24448 (Study P05719)(COMPLETED)
• Quetiapine in the Treatment of Psychotic Depression - a Pilot Study
• Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
• One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
• Treatment of Panic Disorder Among Individuals Consulting Emergency Departments for Non Cardiac Chest Pain
• Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
• Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
• Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
• Treatment of Schizoaffective Disorder Using Mifepristone
• Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
• Anticholinergic Burden in Schizophrenia
• Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
• Cannabinoids, Neural Synchrony, and Information Processing
• Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
• Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
• Biomarker Study of Acamprosate in Schizophrenia
• Schizophrenic Patients in Integrated Care
• Cardio Risk of Acute Schizophrenia Olanzapine Duke
• A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
• A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs
• Effect of Single Dose Intranasal Insulin On Cognitive Function
• Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia
• Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.
• A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
• Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
• A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
• Ziprasidone in the Psychosis Prodrome
• A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
• A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
• A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
• Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
• A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
• Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
• First Episode Schizophrenia and Cannabis-Related Disorder Study
• Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects
• The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning
• Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone
• Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
• A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
• A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
• The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
• A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• The Effects of Rimonabant, on Weight and Metabolic Risk Factors
• Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents
• High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
• Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
• Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
• Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
• Early Detection and Intervention for the Prevention of Psychosis
• An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
• Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
• Health Evaluation of Abilify Long-term Therapy
• Glucose and Lipid Metabolism on Antipsychotic Medication
• Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
• Systematic Evaluation of Antiviral Medication in Schizophrenia
• Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
• Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
• Efficacy and Safety of Quetiapine in Treating Affective Symptoms of Patients With First-episode psychosis-a Pilot Study
• Equivalence of Generic Clozapine to Orally Dissolving Clozapine in Schizophrenia or Schizoaffective Disorder
• Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
• A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
• Varenicline Adjunctive Treatment in Schizophrenia
• Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
• ACP-104 in Acutely Psychotic Subjects With Schizophrenia
• Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
• FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
• Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
• A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
• Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
• Donepezil Double Blind Trial for ECT Memory Disfunction
• Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia
• RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice
• Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
• Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
• Rapid Tranquillization Trial: TREC-India II
• Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
• Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)
• Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)
• Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers
• Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
• Zyprexa and Task Engagement in Schizophrenia
• Effects of Pentazocine Versus Lorazepam on Manic Symptoms
• Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
• Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
• Phase III/Seroquel SR Bipolar Depression Monotherapy - US
• Phase 3 /Seroquel SR Acute Mania Monotherapy - US
• Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
• A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment
• Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
• Antipsychotic Discontinuation in Alzheimer's Disease
• Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.
• Study to Compare Two Formulations of Lamotrigine in Healthy Subjects
• Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
• Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone
• Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
• Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
• PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
• Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
• Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
• Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder
• An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
• A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
• Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
• The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
• Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis
• Tetrabenazine for Partial Responders
• Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
• A Definitive Estrogen Patch Study (ADEPT)
• Multicomponent Risk Factor Intervention for People With a Severe Mental Illness: a Feasibility Study
• Clinical Trial of Dipyridamole in Schizophrenia
• Switch Study of Existing Atypical Antipsychotics to Bifeprunox
• Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression
• Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia
• Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
• Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
• Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
• Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
• Galantamine for Cognition in People With Schizophrenia
• Nicotine Replacement Therapy for Smoking Cessation in Schizophrenia
• Smoking Relapse Prevention in Schizophrenia
• Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
• Modafinil as an Adjunctive on Cognitive Functioning in Patients With Schizophrenia
• Optimizing Response in Psychosis Study
• Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
• Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
• A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
• Specialized Treatment Early in Psychosis (STEP)
• A Clinical Trial on the Antipsychotic Properties of Cannabidiol
• Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
• Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
• Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
• Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
• Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
• High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
• A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
• A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)
• A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
• PET Neuroimaging of [11C]Mirtazapine
• Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
• Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes
• Study of Amantadine for Weight Stabilization During Olanzapine Treatment
• Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
• A Registry of Treatment Adherence for Patients With Schizophrenia
• Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
• Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
• Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717)
• Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
• Risperidone LA Heathcare Resource Study
• CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
• An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
• Brain Imaging and Mental Disorders of Aging Intervention
• Combination Of PAXIL Tablet And Benzodiazepines
• Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache
• Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
• Fast Titration Of Quetiapine Versus Currently Approved Titration
• A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
• A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
• A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
• A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
• A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
• A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
• A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment
• D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
• D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
• Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-ac
• A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
• Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
• Efficacy of Galantamine to Treat Schizophrenia
• Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
• Safety Study of ORG 34517 for Major Depression With Psychotic Features
• The Effects of Aripiprazole on Patients With Metabolic Syndrome
• Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
• Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
• Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills
• A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia
• A Comparative Study of New Medications for Psychosis in Adolescents
• Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
• A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease
• A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
• A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845)
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
• Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846)
• Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)
• Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)
• A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
• Abilify Therapy for Reducing Comorbid Substance Abuse
• A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
• Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
• Clinical Estradiol Trial in Women With Schizophrenia
• The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
• Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
• A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
• Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
• Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
• Indicated Prevention of Psychotic Disorders With Low-dose Lithium
• Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
• Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication
• Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
• Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
• Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
• Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
• Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
• Serotonin 1A Agonists and Cognition in Schizophrenia
• Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
• L-carnosine for Schizophrenia
• Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
• Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
• V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis
• Treatment of Depression With Quetiapine
• Treatment of Major Depressive Disorder With Psychotic Features.
• Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
• Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
• Alcoholism and Schizophrenia: Effects of Clozapine
• Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
• Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
• Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
• Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
• Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
• Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
• An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
• Naltrexone Treatment of Alcohol Abuse in Schizophrenia
• Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study
• To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
• Valnoctamide in Mania
• Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
• Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
• Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
• Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
• Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
• Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
• A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
• Methylphenidate for Depressed Cancer Patients Receiving Palliative Care
• An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
• A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
• Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
• The Effects of Risperidone and Olanzapine on Thinking
• Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
• Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
• Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
• Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
• Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
• Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
• Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
• Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
• Effects of Modafinil on Brain Function in Patients With Schizophrenia
• Study of Pharmacotherapy of Psychotic Depression
• Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1
• The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
• Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)
• Broad Effectiveness: Study With Aripiprazole
• A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
• CAFE Comparison of Atypicals in First Episode of Psychosis
• Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
• A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.
• Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
• Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder
• Treatment of Behavioral Symptoms in Alzheimer's Disease
• To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
• Glycine to Treat Psychotic Disorders in Children
• Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
• Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
• Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
• New Drugs in the Treatment of Mood Disorders
• Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)